Drugs / ORL-1G
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03404856 | Oct 2017 → Oct 2019 | PGM1-congenital disorder of glycosylation | Orpha Labs | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORL-1G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03404856 ↗ |
| Route | Oral | “Oral ORL-1G - D-galactose” NCT03404856 ↗ |